Epitope Editing in Hematopoietic Cells Enables Protection From CD45-directed Immunotherapies For The Treatment Of Blood Cancers And HIV Reservoir Elimination

In this webinar, Dr. Nils Wellhausen of the University of Pennsylvania shares groundbreaking insights into the potential of epitope editing to revolutionize immunotherapies for blood cancers and HIV reservoir elimination. He covers:

• Epitope Editing for Targeted Therapy: Dr. Wellhausen and team developed an epitope-edited hematopoietic stem cell and CAR-T cell pair enabling CD45-directed immunotherapies with reduced off-tumor toxicity while preserving CD45 function.
• Effective Against Blood Cancers: Epitope-edited CD45 CAR-T cells showed efficacy in targeting diverse blood cancers while maintaining healthy hematopoiesis through regeneration by edited hematopoietic stem cells.
• Versatility: The CD45 platform demonstrated compatibility with multiple therapeutic modalities, including bispecific T-cell engagers (BTEs), broadening its applications across hematopoietic diseases, including HIV.
• HIV Reservoir Eradication: Multiplex base editing of CD45 and CCR5 generated HIV-resistant CART45 cells that successfully depleted HIV-infected CD4+ T cells in mouse models.
• Advanced Editing Analysis: The Tapestri Genome Editing Solution characterized editing outcomes, revealing high co-occurrence of precise edits with minimal off-target effects, ensuring the reliability of the editing approach.